Inhibitors of bacterial topoisomerases: Mechanisms of action and resistance and clinical aspects

Planta Medica

Volumn 67, Issue 1, 2001, Pages 3-12

  Heisig, P ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Bacteria and antibiotic resistance; Bacterial topoisomerase; Fluoroquinolone

Indexed keywords

BACTERIAL DNA; CINODINE; CIPROFLOXACIN; CLEROCIDIN; CLINAFLOXACIN; CLOROBIOCIN; COUMAMYCIN A1; CYCLOTHIALIDINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; ENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; GR 122222X; GREPAFLOXACIN; GYRASE INHIBITOR; ISOQUERCITRIN; LEVOFLOXACIN; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; NOVOBIOCIN; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RUTOSIDE; SPARFLOXACIN; TROVAFLOXACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL MUTATION; BONE INFECTION; DRUG STRUCTURE; ENTEROBACTERIACEAE; ENZYME INHIBITION; ESCHERICHIA COLI; HUMAN; INHIBITION KINETICS; NONHUMAN; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; REVIEW; SEPSIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; URINARY TRACT INFECTION;

4-QUINOLONES; ANTI-INFECTIVE AGENTS; CARBOHYDRATE SEQUENCE; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, MICROBIAL; ENZYME INHIBITORS; MOLECULAR STRUCTURE; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

BACTERIA (MICROORGANISMS); ENTEROBACTERIA; ENTEROBACTERIACEAE; ESCHERICHIA COLI; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0035098907     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-10635     Document Type: Review

References (97)

1. Harnessing the power of the genome in the search for new antibiotics
2. DNA topoisomerases
3. Interaction between DNA and an Escherichia coli protein omega
4. DNA gyrase: An enzyme that introduces superhelical turns into DNA
5. DNA gyrase as a drug target
6. DNA gyrase: Structure and function
7. Structure and mechanism of DNA topoisomerase II
8. New topoisomerase essential for chromosome segregation in E. coli
9. The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replication
10. The peptide antibiotic microcin B17 induces double-strand cleavage of DNA mediated by E. coli DNA gyrase
11. Mode of action of GR122222X, a novel inhibitor of bacterial DNA gyrase
12. In vitro inhibition of bacterial DNA gyrase by cinodine, a glycocinnamoylspermidine antibiotic
13. Characterization of a cinodine-resistant mutant of Escherichia coli
14. Biological characterization of cyclothialidine, a new DNA gyrase inhibitor
15. Cyclothialidine analogs, novel DNA gyrase inhibitors
16. Glycosylated flavones as selective inhibitors of topoisomerase IV
17. The interaction between coumarin drugs and DNA gyrase
18. Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase
19. Energy coupling in DNA gyrase and the mechanism of action of novobiocin
20. Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth
21. 1.8-Naphthyridine derivatives, a new class of chemotherapy agents
22. Structure-activity relationships of antibacterial 6.7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids
23. Quinolone Antimicrobial Agents. Activity in vitro of the quinolone
24. Expertengruppe der Paul-Ehrlich-Gesellschaft. Einteilung der fluorchinolone
25. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin
26. Fluoroquinolone action in mycobacteria: Similarity with effects in Escherichia coli and detection by cell lysate viscosity
27. Comparative activities of clinafloxacin against Gram-positive and -negative bacteria
28. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates
29. Quinolone antibacterials. The in vitro antibacterial activity of quinolones: A review
30. Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones
31. Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages
32. In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a
33. In-vitro activity of quinolones and macrolides against mycobacteria
34. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'
35. Mechanism of action of nalidixic acid on Escherichia coli (I)
36. Mechanism of action of nalidixic acid on Escherichia coli (II)
37. Nalidixic acid resistance: A second genetic character involved in DNA gyrase activity
38. Induction of the SOS response by new 4-quinolones
39. The SOS regulatory system of Escherichia coli
40. Studies on the mechanism of action of nalidixic acid
41. Degradation of the fluoroquinolone enrofloxacin by wood-rotting fungi
42. Bacterial resistance to the quinolone antimicrobial agents
43. Prävalenz der antibiotikaresistenz bei klinisch wichtigen infeketionserregern in mitteleuropa
44. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli
45. Characterization of clinical isolates of Escherichia coli showing high levels of fluoroquinolone resistance
46. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals
47. gyrA mutations in high-level fluoroquinolone-resistant clinical isolates of Escherichia coli
48. Characterization of fluoroquinolone-resistant mutants of Escherichia coli selected in vitro
49. Escherichia coli K-12 mutants resistant to nalidixic acid: Genetic mapping and dominance studies
50. gyrA and gyrB mutations in quinolone-resistant strains of Escherichia coli
51. Use of a broad-host-rage gyrA plasmid for genetic characterization of fluoroquinolone-resistant gram-negative bacteria
52. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: Decreased drug accumulation associated with membrane changes in addition to OmpF reduction
53. Antibiotic resistance - Recent development and future perspectives, mechanisms and epidemiology of fluoroquinolone resistance in enterobacteriaceae
54. Quinolone resistance determining region in the DNA gyrase gyrA gene of Escherichia coli
55. Mutations in the gyrA gene of a highly flouroquinolone-resistant clinical isolate of Escherichia coli
56. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition
57. Topoisomerase IV is a target of quinolones in Escherichia coli
58. Detection of mutations in ParC in quinolone-resistant clinical isolates of Escherichia coli
59. Quinolone-resistant mutants of Escherichia coli DNA topoisomerase IV ParC gene
60. Neisserin gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates
61. New 4-quinolone derivatives in review
62. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus
63. Structure-activity and structure-side-effect relationships for the quinolone antibacterials
64. Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faecium
65. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis
66. Cloning and characterization of the parC and pare genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: Role in flouroquinolone resistance
67. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: Selective targeting of gyrase or topoisomerase IV by quinolones
68. Factors influencing the uptake of norfloxacin by Escherichia coli
69. Penetration of lipophilic agents with multiple protonation sites into bacterial cells: Tetracyclines and flouroquinolones as examples
70. Antibiotic resistance caused by Gram-negative multidrug efflux pumps
71. Routes of quinolone permeation in Escherichia coli
72. OmpF channel permeability of quinolones and their comparison with beta-lactams
73. From acids to osmZ: Multiple factors influence synthesis of the OmpF and OmpC porins in Escherichia coli
74. Cross-resistance to nalidixic acid, trimethoprim, and chloramphenicol associated with alterations in outer membrane proteins of Klebsiella, Enterobacter, and Serratia
75. Prevention of drug access to bacterial targets: Permeability barriers and active efflux
76. Fleroxacin resistance in Escherichia coli
77. Endogenous active efflux of norfloxacin in susceptible Escherichin coli
78. Active efflux of ofloxacin by a highly quinolone-resistant strain of Proteus vulgaris
79. Resistance of Neisseria gonorrhoeae to antimicrobial hydrophobic agents is modulated by the mtrRCDE efflux system
80. Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa
81. Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa
82. New norfloxacin resistance gene in Pseudomonas aeruginosa PAO
83. The role of mex-gene products in antibiotic extrusion in Pseudomonas aeruginosa
84. Efflux pumps and drug resistance in Gram-negative bacteria
85. Non-target gene mutations in the development of flouroquinolone resistance in Escherichia coli
86. Regulation of chromosomally mediated multiple antibiotic resistance: The mar regulon
87. Proton-dependent multidrug efflux systems
88. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones
89. Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter
90. Prevalence of a putative efflux mechanism among flouroquinolone-resistant clinical isolates of Streptococcus pneumoniae
91. Identification of an efflux pump gene, pmrA, associated with flouroquinolone resistance in Streptococcus pneumoniae
92. Cloning, expression, and enzymatic characterization of Pseudomonas aeruginosa topoisomerase IV
93. Cloning and nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene from strain PAO1 and quinolone-resistant clinical isolates
94. Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii
95. Genetic functional analysis of the multiple antibiotic resistance (mar) locus in Escherichia coli
96. Genes acrA and acrB encode a stress-induced efflux system of Escherichia coli
97. The local repressor AcrR plays a modulating role in the regulation of acrAB genes of Escherichia coli by global stress signals